A Phase III Study Evaluating the Standard Radiation Therapy and Chemotherapy Regimen, With or Without Nimotuzumab, in Unresectable, Locally Advanced Epidermoid Carcinoma of the Head and Neck

Trial Profile

A Phase III Study Evaluating the Standard Radiation Therapy and Chemotherapy Regimen, With or Without Nimotuzumab, in Unresectable, Locally Advanced Epidermoid Carcinoma of the Head and Neck

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2015

At a glance

  • Drugs Nimotuzumab (Primary)
  • Indications Head and neck cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NICAP
  • Sponsors Eurofarma
  • Most Recent Events

    • 24 Jul 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
    • 15 Aug 2013 Planned number of patients changed from 304 to 280 as reported by ClinicalTrials.gov.
    • 15 Aug 2013 Planned initiation date changed from 1 Sep 2011 to 1 Nov 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top